Comments
Drug firm Zydus Cadila on Thursday said it has received approval from the US health regulator to market Isosorbide Dinitrate tablets used to prevent attacks of chest pain.
The drug firm has also received final approval for Desonide Cream, used to treat a variety of skin conditions like eczema, dermatitis, allergies and rash, the company said in a filing to BSE.
“Zydus Cadila has received the final approval from the USFDA to market Isosorbide Dinitrate tablets USP...in the strengths of 5 mg, 10 mg, 20 mg, 30 mg and 40 mg,” the filing said.
The drug is used to prevent attacks of chest pain. It dilates blood vessels, making it easier for blood to flow through them and easier for the heart to pump. It will be manufactured at the Group’s formulations manufacturing facility at Baddi, Himachal Pradesh.
“The group also received the final approval for Desonide Cream (US RLD - Desonide Cream), 0.05 per cent,” the filing said. The drug is a mild corticosteroid, used to treat a variety of skin conditions like eczema, dermatitis, allergies and rash, to reduce swelling, itching and redness that can occur in these types of conditions.
It will be manufactured at the Group’s topical manufacturing facility at Ahmedabad, it said.
The shares of Cadila Healthcare, the listed entity of the group, were trading at ₹251.35, higher by 0.92 per cent on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.